Table 3.
SBP (mm/Hg) | AST (IU/L) | ALT (IU/L) | GGT (IU/L) | DrInC | PHDD | PDD | DPDD | |
---|---|---|---|---|---|---|---|---|
B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | |
Linear Mixed Models (n=1226) | ||||||||
1-level reduction | –6.42 (1.11)*** | –7.87 (2.18)*** | –6.33 (2.09)*** | –26.92 (10.47)* | –19.24 (1.32)*** | –39.89 (1.76)*** | –32.69 (1.62)*** | –4.86 (.36)*** |
2-level reduction | –6.00 (.84)*** | –7.19 (1.55)*** | –6.00 (1.53)*** | –21.84 (7.97)** | –17.40 (1.08)*** | –38.55 (1.45)*** | –33.65 (1.39)*** | –4.16 (.28)*** |
Missing = Failure Models (n=1226) | ||||||||
1-level reduction | –5.69 (1.09)*** | –7.62 (2.09)*** | –6.12 (2.01)** | –25.60 (10.07)* | –18.21 (1.27)*** | –29.71 (1.62)*** | –24.53 (1.49)*** | –3.23 (.31)*** |
2-level reduction | –5.56 (.84)*** | –7.13 (1.53)*** | –5.86 (1.50)*** | –21.37 (7.67)** | –16.84 (1.06)*** | –32.07 (1.41)*** | –28.37 (1.33)*** | –3.25 (.26)*** |
Excluding Abstainers (n=1052) | ||||||||
1-level reduction | –5.14 (1.13)*** | –6.36 (2.15)** | –4.17 (1.99)* | –12.64 (6.82) | –14.39 (1.22)*** | –38.27 (1.77)*** | –28.10 (1.63)*** | –3.54 (.41)*** |
2-level reduction | –4.26 (.89)*** | –5.49 (1.60)** | –3.87 (1.56)* | –8.24 (5.21) | –13.14 (1.02)*** | –38.19 (1.54)*** | –29.34 (1.45)*** | –2.96 (.33)*** |
Note.
p<0.05
p<0.01
p<0.001, B (SE) = Unstandardized regression coefficients (standard error), which can be interpreted as the decrease in outcomes based on achieving at least a 1- and 2-level reduction, at the average of all covariates (covariate effects reported in Supplementary Table 1); SBP=Systolic blood pressure; AST=aspartate aminotransferase; ALT=alanine aminotransferase; GGT=γ-glutamyltransferase; IU/L=International Units per Liter; DrInC = Drinker Inventory of Consequences Total Score; PHDD = Percent heavy drinking days; PDD = Percent drinking days; DPDD = Drinks per drinking day. The reference group for the one-level reduction was no change or an increase in the WHO risk drinking level from baseline to the treatment/follow-up months, and the reference group for the two-level reduction was the one-level reduction, no change, or increase in the WHO risk level from baseline to the treatment/follow-up months.